Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma

Beatrice Anna Zannetti, Paola Tacchetti, Lucia Pantani, Barbara Gamberi, Patrizia Tosi, Serena Rocchi, Claudia Cellini, Sonia Ronconi, Annalisa Pezzi, Katia Mancuso, Ilaria Rizzello, Isola Caratozzolo, Marina Martello, Luca Dozza, Michele Cavo, Elena Zamagni

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

2017 Springer-Verlag GmbH Germany High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is a standard frontline therapy for multiple myeloma (MM). Therapeutic options for patients with relapsed MM after ASCT include novel agents in different combos, salvage ASCT (sASCT), and allogeneic transplant, with no unique standard of care. We retrospectively analyzed 66 MM patients who relapsed after up-front single or double ASCT(s) and received novel agent-based sASCT at five Italian centers. Median event-free survival from up-front ASCT(s) to first relapse (EFS1) was 44 months. Seventy-three percent of patients received sASCT at first disease progression. Re-induction regimens were bortezomib based in 87% of patients. Response to re-induction therapy included complete response (CR) 18%, ≥ very good partial response (VGPR) 48%, and overall response rate (ORR) 83%. Response to sASCT included CR 44%, ≥ VGPR 77%, and ORR 94%. With a median follow-up of 24 months after sASCT, 39 patients experienced disease progression. Median EFS from sASCT (EFS2) was 17 months. Median overall survival from ASCT (OS1) and sASCT (OS2) was 166 and 43 months, respectively. EFS2 and OS2 were significantly shorter in patients with EFS1 ≤ 24 months, in patients who did not receive sASCT at first disease progression and in patients with extramedullary disease (EMD). In multivariate analysis, EFS1 ≤ 24 months was associated with shorter EFS2 and OS2, EMD was associated with shorter EFS2, and < CR after sASCT was associated with shorter OS2. Novel agent-based sASCT is a safe and effective procedure for relapsed MM.
Original languageEnglish
Pages (from-to)1-8
Number of pages8
JournalAnnals of Hematology
DOIs
Publication statusAccepted/In press - Oct 24 2017

Fingerprint

Stem Cell Transplantation
Multiple Myeloma
Disease Progression
Standard of Care
Disease-Free Survival
Germany
Therapeutics
Multivariate Analysis
Transplants
Recurrence
Drug Therapy
Survival

Keywords

  • Multiple myeloma
  • Novel agents
  • Outcomes
  • Relapse
  • Salvage autologous stem cell transplantation

Cite this

Zannetti, B. A., Tacchetti, P., Pantani, L., Gamberi, B., Tosi, P., Rocchi, S., ... Zamagni, E. (Accepted/In press). Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma. Annals of Hematology, 1-8. https://doi.org/10.1007/s00277-017-3140-5

Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma. / Zannetti, Beatrice Anna; Tacchetti, Paola; Pantani, Lucia; Gamberi, Barbara; Tosi, Patrizia; Rocchi, Serena; Cellini, Claudia; Ronconi, Sonia; Pezzi, Annalisa; Mancuso, Katia; Rizzello, Ilaria; Caratozzolo, Isola; Martello, Marina; Dozza, Luca; Cavo, Michele; Zamagni, Elena.

In: Annals of Hematology, 24.10.2017, p. 1-8.

Research output: Contribution to journalArticle

Zannetti, BA, Tacchetti, P, Pantani, L, Gamberi, B, Tosi, P, Rocchi, S, Cellini, C, Ronconi, S, Pezzi, A, Mancuso, K, Rizzello, I, Caratozzolo, I, Martello, M, Dozza, L, Cavo, M & Zamagni, E 2017, 'Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma', Annals of Hematology, pp. 1-8. https://doi.org/10.1007/s00277-017-3140-5
Zannetti, Beatrice Anna ; Tacchetti, Paola ; Pantani, Lucia ; Gamberi, Barbara ; Tosi, Patrizia ; Rocchi, Serena ; Cellini, Claudia ; Ronconi, Sonia ; Pezzi, Annalisa ; Mancuso, Katia ; Rizzello, Ilaria ; Caratozzolo, Isola ; Martello, Marina ; Dozza, Luca ; Cavo, Michele ; Zamagni, Elena. / Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma. In: Annals of Hematology. 2017 ; pp. 1-8.
@article{e3b012ecf8a445ca89783d479e42b3df,
title = "Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma",
abstract = "2017 Springer-Verlag GmbH Germany High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is a standard frontline therapy for multiple myeloma (MM). Therapeutic options for patients with relapsed MM after ASCT include novel agents in different combos, salvage ASCT (sASCT), and allogeneic transplant, with no unique standard of care. We retrospectively analyzed 66 MM patients who relapsed after up-front single or double ASCT(s) and received novel agent-based sASCT at five Italian centers. Median event-free survival from up-front ASCT(s) to first relapse (EFS1) was 44 months. Seventy-three percent of patients received sASCT at first disease progression. Re-induction regimens were bortezomib based in 87{\%} of patients. Response to re-induction therapy included complete response (CR) 18{\%}, ≥ very good partial response (VGPR) 48{\%}, and overall response rate (ORR) 83{\%}. Response to sASCT included CR 44{\%}, ≥ VGPR 77{\%}, and ORR 94{\%}. With a median follow-up of 24 months after sASCT, 39 patients experienced disease progression. Median EFS from sASCT (EFS2) was 17 months. Median overall survival from ASCT (OS1) and sASCT (OS2) was 166 and 43 months, respectively. EFS2 and OS2 were significantly shorter in patients with EFS1 ≤ 24 months, in patients who did not receive sASCT at first disease progression and in patients with extramedullary disease (EMD). In multivariate analysis, EFS1 ≤ 24 months was associated with shorter EFS2 and OS2, EMD was associated with shorter EFS2, and < CR after sASCT was associated with shorter OS2. Novel agent-based sASCT is a safe and effective procedure for relapsed MM.",
keywords = "Multiple myeloma, Novel agents, Outcomes, Relapse, Salvage autologous stem cell transplantation",
author = "Zannetti, {Beatrice Anna} and Paola Tacchetti and Lucia Pantani and Barbara Gamberi and Patrizia Tosi and Serena Rocchi and Claudia Cellini and Sonia Ronconi and Annalisa Pezzi and Katia Mancuso and Ilaria Rizzello and Isola Caratozzolo and Marina Martello and Luca Dozza and Michele Cavo and Elena Zamagni",
year = "2017",
month = "10",
day = "24",
doi = "10.1007/s00277-017-3140-5",
language = "English",
pages = "1--8",
journal = "Annals of Hematology",
issn = "0939-5555",
publisher = "Springer Verlag",

}

TY - JOUR

T1 - Novel agent-based salvage autologous stem cell transplantation for relapsed multiple myeloma

AU - Zannetti, Beatrice Anna

AU - Tacchetti, Paola

AU - Pantani, Lucia

AU - Gamberi, Barbara

AU - Tosi, Patrizia

AU - Rocchi, Serena

AU - Cellini, Claudia

AU - Ronconi, Sonia

AU - Pezzi, Annalisa

AU - Mancuso, Katia

AU - Rizzello, Ilaria

AU - Caratozzolo, Isola

AU - Martello, Marina

AU - Dozza, Luca

AU - Cavo, Michele

AU - Zamagni, Elena

PY - 2017/10/24

Y1 - 2017/10/24

N2 - 2017 Springer-Verlag GmbH Germany High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is a standard frontline therapy for multiple myeloma (MM). Therapeutic options for patients with relapsed MM after ASCT include novel agents in different combos, salvage ASCT (sASCT), and allogeneic transplant, with no unique standard of care. We retrospectively analyzed 66 MM patients who relapsed after up-front single or double ASCT(s) and received novel agent-based sASCT at five Italian centers. Median event-free survival from up-front ASCT(s) to first relapse (EFS1) was 44 months. Seventy-three percent of patients received sASCT at first disease progression. Re-induction regimens were bortezomib based in 87% of patients. Response to re-induction therapy included complete response (CR) 18%, ≥ very good partial response (VGPR) 48%, and overall response rate (ORR) 83%. Response to sASCT included CR 44%, ≥ VGPR 77%, and ORR 94%. With a median follow-up of 24 months after sASCT, 39 patients experienced disease progression. Median EFS from sASCT (EFS2) was 17 months. Median overall survival from ASCT (OS1) and sASCT (OS2) was 166 and 43 months, respectively. EFS2 and OS2 were significantly shorter in patients with EFS1 ≤ 24 months, in patients who did not receive sASCT at first disease progression and in patients with extramedullary disease (EMD). In multivariate analysis, EFS1 ≤ 24 months was associated with shorter EFS2 and OS2, EMD was associated with shorter EFS2, and < CR after sASCT was associated with shorter OS2. Novel agent-based sASCT is a safe and effective procedure for relapsed MM.

AB - 2017 Springer-Verlag GmbH Germany High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is a standard frontline therapy for multiple myeloma (MM). Therapeutic options for patients with relapsed MM after ASCT include novel agents in different combos, salvage ASCT (sASCT), and allogeneic transplant, with no unique standard of care. We retrospectively analyzed 66 MM patients who relapsed after up-front single or double ASCT(s) and received novel agent-based sASCT at five Italian centers. Median event-free survival from up-front ASCT(s) to first relapse (EFS1) was 44 months. Seventy-three percent of patients received sASCT at first disease progression. Re-induction regimens were bortezomib based in 87% of patients. Response to re-induction therapy included complete response (CR) 18%, ≥ very good partial response (VGPR) 48%, and overall response rate (ORR) 83%. Response to sASCT included CR 44%, ≥ VGPR 77%, and ORR 94%. With a median follow-up of 24 months after sASCT, 39 patients experienced disease progression. Median EFS from sASCT (EFS2) was 17 months. Median overall survival from ASCT (OS1) and sASCT (OS2) was 166 and 43 months, respectively. EFS2 and OS2 were significantly shorter in patients with EFS1 ≤ 24 months, in patients who did not receive sASCT at first disease progression and in patients with extramedullary disease (EMD). In multivariate analysis, EFS1 ≤ 24 months was associated with shorter EFS2 and OS2, EMD was associated with shorter EFS2, and < CR after sASCT was associated with shorter OS2. Novel agent-based sASCT is a safe and effective procedure for relapsed MM.

KW - Multiple myeloma

KW - Novel agents

KW - Outcomes

KW - Relapse

KW - Salvage autologous stem cell transplantation

UR - http://www.scopus.com/inward/record.url?scp=85032016472&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85032016472&partnerID=8YFLogxK

U2 - 10.1007/s00277-017-3140-5

DO - 10.1007/s00277-017-3140-5

M3 - Article

SP - 1

EP - 8

JO - Annals of Hematology

JF - Annals of Hematology

SN - 0939-5555

ER -